Regeneron Pharma (REGN) PT Raised to $1,115 at Morgan Stanley, 'Numerous catalysts ahead; refreshing estimates'
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison raised the price target on Regeneron Pharma (NASDAQ: REGN) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
